Results 11 to 20 of about 22,142 (188)

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells [PDF]

Brazilian Journal of Medical and Biological Research
Despite the widespread use of R-CHOP therapy in diffuse large B-cell lymphoma (DLBCL), the therapeutic efficacy for this disease remains suboptimal, primarily due to the heterogeneity of refractory and/or relapsed diseases.
Fengbo Jin, Limei He, Yingying Chen, Wanlu Tian, Lixia Liu, Ling Ge, Wei Qian, Leiming Xia, Mingzhen Yang   +8 more
doaj   +3 more sources

Mitigating Ibrutinib‐Induced Ventricular Arrhythmia and Cardiac Dysfunction With Metformin [PDF]

Cancer Innovation
Background Ibrutinib is a first‐line drug that targets Bruton's tyrosine kinase for the treatment of B cell cancer. However, cardiotoxicity induced by ibrutinib is a major side effect that limits its clinical use.
Pengsha Li, Daiqi Liu, Pan Gao, Ming Yuan, Zhiqiang Zhao, Yue Zhang, Zandong Zhou, Qingling Zhang, Meng Yuan, Xing Liu, Gary Tse, Guangping Li, Qiankun Bao, Tong Liu   +13 more
doaj   +4 more sources

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner

Pharmaceutics, 2022
BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown.
Jia Liu, Zhuojun Liu, Jing Zhang, Xiaofang Chen, Junge Chen, Linlin Sui, Jian Yu   +6 more
doaj   +2 more sources

Electrocardiographic Changes Associated With Ibrutinib Exposure

Cancer Control, 2020
Although ibrutinib-associated atrial and ventricular arrhythmias have been well described, there is little information about ibrutinib’s effects on other electrocardiographic parameters, particularly the QT interval.
Michael G. Fradley MD, Allan Welter-Frost MD, Matthew Gliksman BS, Josephine Emole MD, Federico Viganego MD, Dae Hyun Lee MD, Bijal Shah MD, Julio C. Chavez MD, Javier Pinilla-Ibarz MD, PhD, Matthew B. Schabath PhD   +9 more
doaj   +3 more sources

Extrahepatic metabolism of ibrutinib [PDF]

, 2021
Ibrutinib is a first-in-class Bruton's kinase inhibitor used in the treatment of multiple lymphomas. In addition to CYP3A4-mediated metabolism, glutathione conjugation can be observed.
Rood, Johannes J M, Wasmann, Roeland E, Masereeuw, Rosalinde, van Haren, Matthijs J, Sparidans, Rolf W, Jamalpoor, Amer, Schinkel, Alfred H, Janssen, Manoe J, Beijnen, Jos H, van Hoppe, Stephanie   +9 more
core   +3 more sources

Mechanism of Covalent Binding of Ibrutinib to Bruton’s Tyrosine Kinase revealed by QM/MM Calculations [PDF]

, 2020
Ibrutinib is the first covalent inhibitor of Bruton’s tyrosine kinase (BTK) to be used in the treatment of B-cell cancers. Understanding the mechanism of covalent inhibition is crucial for the design of safer and more selective covalent inhibitors that ...
Angus, Voice, Adrian, Mulholland, Rebecca, Twidale, Herman, Van Vlijmen, Gary, Tresadern   +4 more
core   +1 more source

Ibrutinib-related uveitis: A case series

American Journal of Ophthalmology Case Reports, 2022
Purpose: Four cases of ibrutinib-related uveitis are presented, which are to the best of our knowledge the first in the literature. Possible mechanisms of ibrutinib-mediated uveitis are explored.
Zelia K. Chiu, Jonathan KS. Goh, Cecilia Ling, Ming-Lee Lin, Anthony J. Hall   +4 more
doaj   +1 more source

Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Advances in Hematology, 2022
Ibrutinib-based therapies are costly and require continuous administration. We hypothesized combining BTK inhibition with anti-CD20 monoclonal antibodies would yield deep remissions allowing discontinuation.
Januario E. Castro, Paula A. Lengerke-Diaz, Juliana Velez Lujan, Michael Y. Choi, Eider F. Moreno-Cortes, Jose V. Forero, Juan Esteban Garcia-Robledo, Chaja Jacobs, Colin McCarthy, Alaina Heinen, Carlos I. Amaya-Chanaga, Thomas J. Kipps   +11 more
doaj   +1 more source

Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice

Journal of Neuroinflammation, 2018
Background The FDA-approved small-molecule drug ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling.
Hye Yeon Nam, Jin Han Nam, Gwangho Yoon, Ju-Young Lee, Youngpyo Nam, Hye-Jin Kang, Hyun-Ji Cho, Jeongyeon Kim, Hyang-Sook Hoe   +8 more
doaj   +1 more source

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Haematologica, 2017
The first-in-class Bruton’s tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cell malignancies; however, atrial fibrillation (AF) has been reported in 6–16% of ibrutinib patients.
Jennifer R. Brown, Javid Moslehi, Susan O’Brien, Paolo Ghia, Peter Hillmen, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Thomas J. Kipps, Steven Coutre, Marie-Sarah Dilhuydy, Paula Cramer, Alessandra Tedeschi, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Angela Howes, Michael Todd, Jessica Vermeulen, Danelle F. James, Fong Clow, Lori Styles, Rudy Valentino, Mark Wildgust, Michelle Mahler, Jan A. Burger   +26 more
doaj   +1 more source